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Background: There has been accumulating evidence associating diabetes mellitus and cardiovascular dysfunctions.
However, most of the studies are focused on the late stages of diabetes and on the function of large arteries. This
study aimed at characterizing the effects of the early phase of diabetes mellitus on the cardiac and vascular
function with focus on the intact coronary microvasculature and the oxidative stress involved.
Materials and methods: Zucker diabetic fatty rats and their lean littermates fed with standard diet A04 (Safe) were
studied at the 11th week of age. Biochemical parameters such as glucose, insulin and triglycerides levels as well as
their oxidative stress status were measured. Their hearts were perfused ex vivo according to Langendorff and their
cardiac activity and coronary microvascular reactivity were evaluated.
Results: Zucker fatty rats already exhibited a diabetic state at this age as demonstrated by the elevated levels of
plasma glucose, insulin, glycated hemoglobin and triglycerides. The ex vivo perfusion of their hearts revealed a
decreased cardiac mechanical function and coronary flow. This was accompanied by an increase in the overall
oxidative stress of the organs. However, estimation of the active form of endothelial nitric oxide synthase and
coronary reactivity indicated a preserved function of the coronary microvessels at this phase of the disease.
Diabetes affected also the cardiac membrane phospholipid fatty acid composition by increasing the arachidonic
acid and n-3 polyunsaturated fatty acids levels.
Conclusions: The presence of diabetes, even at its beginning, significantly increased the overall oxidative stress of
the organs resulting to decreased cardiac mechanical activity ex vivo. However, adaptations were adopted at this
early phase of the disease regarding the preserved coronary microvascular reactivity and the associated cardiac
phospholipid composition in order to provide a certain protection to the heart.
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The prevalence of Type 2 Diabetes (T2D) is increasing
at an alarming rate assuming epidemic dimensions in
industrialized societies [1]. Individuals with T2D have
increased risk for developing cardiovascular diseases
(CVDs), which is the main cause of early mortality and
morbidity in the Western world [2]. Insulin resistance
and T2D usually result from excess intake of deleterious
nutrients such as saturated and trans fatty acids [3].
Consequent metabolic changes such as hyperinsulinemia
and hyperglycemia [4] can provoke vascular lesions and
endothelial dysfunctions at both micro- and macro-
circulations [5-8]. The vulnerability of the coronary
circulation to the diabetic milieu can lead to endothelial
dysfunction at this bed, which consists a significant bio-
marker of early coronary artery disease independently of
atherosclerosis [9].
An accurate experimental model in order to clarify the
mechanisms responsible for the pathophysiology of dia-
betes evolution and its complications is the inbred
Zucker diabetic fatty (ZDF) rat. The homozygous fa/fa
Zucker rat exhibits hyperphagia caused by a non-
functioning leptin receptor. This leads to the develop-
ment of obesity, hyperglycemia, hyperinsulinemia and
finally diabetes at a young age [10,11]. Previous studies
on these rats in the later stages of diabetes have demon-
strated that chronic hyperglycemia and hyperlipidemia
can result in inflammation [12,13], increased oxidative
stress and vascular dysfunction [14,15]. Coppey et al. [16]
have shown that the endothelium-mediated responses to
acetylcholine (Ach) are attenuated in epineurial arterioles
of the sciatic nerve in diabetic ZDF rats. A key feature is
the reduced production of nitric oxide (NO), a compound
which mediates endothelium-dependent vasorelaxation
and inhibits inflammation. In T2D, its bioavailability
can be diminished either by the impaired insulin sig-
naling either by the action of reactive oxygen species
(ROS) [17].
Although the consequences of the later stages of T2D
on the cardiac and endothelial function are well charac-
terized, less is known concerning the early period of the
disease where an interventional treatment may be more
effective. Furthermore, most studies are focused on the
endothelial function and perfusion of large arteries
[18-20] and few on the coronary function of resistance
vessels. The primary function of the coronary microcir-
culation is to optimize nutrient and oxygen supply to
the heart in response to any metabolic demand by co-
ordinating the resistances within different microvascular
domains, each governed by distinct regulatory mecha-
nisms [21]. Coronary resistance arteries are capable of
adapting to acute or chronic increases in blood flow
leading to an increased NO-mediated relaxation and a
consequent enlargement of their diameter. Furthermore,endothelial dysfunction in resistance arteries seems to pre-
cede that of large arteries [22]. Although there is strong
evidence indicating that T2D is associated with impaired
vasodilator responses of both peripheral and coronary ves-
sels, Oltman et al. [22] have demonstrated that in diabetic
young (8- to 12 wk old) ZDF rats the coronary arteriolar
dilation to Ach of isolated microvessels is preserved. How-
ever, these in vitro studies isolate the coronary system
from the cardiac environment and its influences.
Thus, this work aimed at studying the ex vivo cardiac
and coronary vascular functions of young ZDF rats and
at characterizing the levels of oxidative stress in their
organs. The endothelial function of the intact coronary
microvasculature was assessed in terms of endothelium-
dependent and -independent vasodilatations in an ex vivo
heart perfusion model at this phase of T2D. The NO pro-
duction in aortas and hearts was evaluated indirectly by
estimating the degree of phosphorylation of the endothe-
lial NO-synthase (eNOS) at serine 1177 (Ser1177) and the
iNOS levels in the heart. Finally, the fatty acid profile of
cardiac membrane phospholipids was evaluated since any
modification at this level leads to functional changes in
lipid-protein interactions and related signaling pathways.
Methods
Animals and experimental design
All experiments followed the European Union recom-
mendations concerning the care and use of laboratory
animals for experimental and scientific purposes. All ani-
mal work was approved by the local board of ethics for
animal experimentation (Cometh) and notified to the
research animal facility of our laboratory (authorization
n° 38 07 23). The performed research was in compliance
with the ARRIVE guidelines on animal research [23].
Ten ZDF and eleven Zucker lean (ZL) male rats were
obtained from Charles Rivers (L’Arbresle, France) at 7
weeks (wk) of age. Rats were housed in a temperature-
and humidity-controlled facility on a 12-h light:dark
cycle. The two groups were fed ad libitum with a stand-
ard carbohydrate diet (A04, Safe, Augy, France), they
had free access to water and their body weight and food
intake were recorded twice weekly. The composition of
the chosen diet by weight is 60% assimilable glucides
(52% mainly starch and cellulose), 16% proteins and 3%
fat. After analysis of the fatty acid composition of our
diet we found a formula with approximately 24% of satu-
rated fatty acids (SFAs), 23% of monounsaturated fatty
acids (MUFAs), 48% of n-6 polyunsaturated fatty acids
(PUFAs) and 4.5% of n-3 PUFAs. Plasma glucose and
glycated hemoglobin (HbA1c) concentrations were also
measured weekly via the tail vein.
On the day of the experiment, the rats were weighed
and heparinized (1500 I.U./kg) intraperitoneally 30 mi-
nutes (min) before their decapitation. Blood samples
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retroperitoneal and mesenteric adipose tissues were
weighed for determination of the abdominal fat mass
[24]. Perfusion experiments were performed twice a day
by alternating the rat phenotypes. The first experiment
was performed between 8:00 a.m. and 8:30 a.m. and the
second one between 12:30 p.m. and 1:00 p.m.
Cardiac function study
All rats underwent ex vivo Langendorff assessment of their
cardiac function. For this reason, a rapid thoracotomy was
performed and the heart was immediately collected in
Krebs-Henseleit solution maintained at 4°C. It was then
rapidly (less than one minute to avoid problems of cellular
damages or preconditioning) perfused at constant pressure
according to the Langendorff mode with a Krebs–
Henseleit buffer containing (in mM) NaCl 119, MgSO4
1.2, KCl 4.8, NaHCO3 25, KH2PO4 1.2, CaCl2 1.2 and glu-
cose 11 mM as sole energy substrate. The perfusion buffer
used was similar for both groups in order to minimize the
variables studied. The buffer was maintained at 37°C and
continuously oxygenated with carbogen (95% O2/5%
CO2). A latex balloon connected to a pressure probe was
inserted into the left ventricle and filled until the diastolic
pressure reached a value of 7–8 mmHg. This allowed the
monitoring of heart rate, systolic, diastolic and left ven-
tricle developed pressures throughout the perfusion proto-
col. A pressure gauge inserted into the perfusion circuit
just upstream the aortic cannula allowed the evaluation of
the coronary pressure. The heart was perfused at constant
pressure of 59 mmHg [25] for 30 minutes and the coron-
ary flow for each heart was evaluated by weight determin-
ation of 1-min collected samples at the 25th min of
perfusion. After this period, the heart was perfused at con-
stant flow conditions, for which the flow rate was adjusted
in order to obtain the same coronary flow as in the prepar-
ation at constant pressure. The systolic, diastolic and left
ventricle developed pressures as well as the heart rate was
determined after 10 min of perfusion at forced flow in
order to allow a satisfying stabilization of the heart. The
left ventricle developed pressure was calculated by
subtracting the diastolic pressure to the systolic pressure.
The rate-pressure product (RPP) was defined as the prod-
uct of left ventricle developed pressure and heart rate and
was used as indicator of the cardiac mechanical work [26].
All the parameters were recorded and analyzed with a
computer using the HSE IsoHeart software (Hugo Sachs
Elektronik, March-Hugstetten, Germany).
Coronary reactivity
After the evaluation of the cardiac function at constant
flow, we assessed the effects of diabetes on the coronary
reactivity. After the 10-min equilibration period at con-
stant flow, the coronary tone was raised by using thethromboxane analog U46619 (30nM), which was con-
stantly infused into the perfusion system near the aortic
cannula at a rate never exceeding 1.5% of the coronary
flow. This allowed the obtainment of a coronary pres-
sure between 120 and 130 mmHg. In our model of per-
fusion at forced flow, the aortic pressure equaled the
coronary pressure and changes in the coronary tone
triggered modifications of the aortic pressure. Changes
in aortic perfusion pressure were thus used to monitor
changes in coronary tone. Furthermore, this experi-
mental model allows the evaluation of the coronary
microvasculature reactivity since the coronary resist-
ance vessels determine the overall coronary pressure.
Relaxation responses to Ach (4, 10, 20, 40, 60, 80 and
100 pmoles) and sodium nitroprusside (SNP, 100, 200,
400, 600, 800 and 1000 pmoles) injections were deter-
mined reflecting the endothelial-dependent vasodilatation
(EDD) and endothelium-independent vasodilatation (EID)
respectively.
The dilatation amplitude was calculated as the ratio
between the maximal decrease in the coronary pressure
and the coronary pressure just before the injection of
the dilatation agents. Since the heart weight and coron-
ary volume were subjected to intra- and inter-group
variations, a correction was performed to normalise the
input-function of the vasodilatation agents according to
the coronary flow. The dose–response curve between the
amount of vasodilatation agent injected and the maximal
vasodilatation was then fitted to a logarithm function for
each heart which allowed the fulfillment of statistical ana-
lyses. Moreover, the vasodilatation activity of the endothe-
lial cells was also estimated from the corrected EDD and
EID curves. For each heart and each injected Ach dose,
the amount of SNP (reflecting the amount of vasodilator
agents) necessary to obtain the same percentage of Ach-
induced vasodilatation was extracted from the EID curve
according to the formula: endothelial cell vasodilatation
activity (ECVA) = e [(% Ach-induced dilatation - b)/a], where a
and b are the coefficients of the theoretical EID curve.
The results were expressed in pmole equivalents of
nitroprusside. At the end of the perfusion protocol, the
hearts were freeze-clamped and stored at −80°C until the
biochemical analyses were performed.
Oxidative stress measurements
Plasma oxidative stress
Protein oxidation in the plasma was evaluated by the
disappearance of protein thiol groups [27]. Plasma thiols
were assayed in 20 μl of plasma, using 5,5'-dithiobis(2-
nitrobenzoic acid (DTNB)) for deriving the thiol groups.
The calibration curve was obtained by mixing two stock
solutions of N-acetyl cystein (NAC) in the range of
0.125–0.6 mmol/l. Standards and plasma samples were
measured spectrophotometrically at 415 nm (Hitachi 912,
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phate buffer 50 mM, EDTA 100 mM, pH 8 and bis-5,5'-
dithio-bis(2-nitrobenzoic acid) 10 mM.
The antioxidant status of the plasma was evaluated
using ferric reducing antioxidant power (FRAP) assay as
a global marker of the antioxidant power. The FRAP
assay uses antioxidants as reductants in a redox-linked
colorimetric method. In this assay, at low pH, a ferric-
tripyridyltriazine (FeIII-TPTZ) complex is reduced to the
ferrous form, which is blue and monitored by measuring
the change in absorption at 593 nm. The change in
absorbance is directly proportional to the reducing
power of the electron-donating antioxidants present in
plasma. The absorbance change is translated into a
FRAP value (in μmol/l) by relating the change of absorb-
ance at 593 nm of test sample to that of a standard solu-
tion of known FRAP value.
Glutathione peroxidase (GPx) activity, which is a
seleno-enzyme involved in protection against hydrogen
peroxide (H2O2) was evaluated in plasma samples by the
modified method of Gunzler [28] using terbutyl hydroper-
oxide (Sigma Chemical Co, Via Coger, Paris, France) as a
substrate instead of hydrogen peroxide. The principle of
the assay is based on the coupled reaction with glutathi-
one reductase (GR). Oxidized glutathione (GSSG), pro-
duced upon reduction of an organic hydroperoxide by
GPx with glutathione (GSH) as electron donor, is recycled
to its reduced state by GR and NADPH. The oxidation of
NADPH to NADP+ is accompanied by a decrease in
absorbance at 340 nm. The rate of decrease in the A340 is
directly proportional to the GPx activity in the sample.
The assay was performed at 25°C and pH 7.0 that allowed
a stable concentration of GSH in the reaction medium.
Cardiac oxidative stress
Lactate and pyruvate released in the coronary efflu-
ents were spectrophotometrically assayed according to
Bergmeyer [29]. The lactate to pyruvate ratio was calcu-
lated to estimate the cytosolic redox potential (NADH/
NAD+) [30-32]. This is a highly specific assay using the
enzyme lactate dehydrogenase (LDH) to catalyze the
reversible reaction of pyruvate and NADH to lactate and
NAD+. The catalytic action of LDH permits spectro-
photometric measurement at 340 nm (spectrophotom-
eter ULTROSPECTM 2100 pro, Amersham Biosciences,
Uppsala, Sweden) of lactate production in terms of the
generation of NADH in the reaction shown above. To
measure lactate, the reaction is carried out from right to
left with excess NAD+. To force the reaction to comple-
tion in this direction, it is necessary to trap formed
pyruvate with hydrazine. The increased absorbance at
340 nm due to NADH formation becomes a mole-
to-mole measure of the lactate originally present in the
sample.Lipid peroxidation was assessed by measuring the con-
centration of thiobarbituric acid reactive substances
(TBARS) in cardiac homogenates [33]. TBARS were de-
termined using the fluorimetric determination of
malondialdehyde – thiobarbituric acid complex after
acid hydrolysis at 95°C and extraction with n-butanol.
Briefly, tissue homogenate aliquots were placed in poly-
ethylene tubes mixed with TBA (thiobarbituric acid)/
perchloric acid 7% (2:1, v/v) and incubated at 95°C. After
cooling, n-butanol was added for the extraction and then
the aliquots were centrifuged for 10 min at 35000 g. The
supernatant was used to read the fluorescence at excita-
tion and emission wavelengths of 532 and 553 nm
respectively. The TBARS calculated were normalized to
the content of polyunsaturated fatty acids of cardiac
membrane phospholipids since it differed between
groups. The protein thiol groups and FRAP assays were
also evaluated in cardiac homogenates as described pre-
viously for the plasma.
Cardiac mitochondrial oxidative stress
The ratio between the activities of aconitase and fuma-
rase of the myocardium was calculated as an indicator of
mitochondrial ROS production. Mitochondrial aconitase
is sensitive to inactivation by superoxide due to the sus-
ceptibility of its iron-sulfur core to oxidation; however,
fumarase is unaffected. Thus, the activity ratio of
aconitase to fumarase was calculated as an indicator of
the presence of mitochondrial ROS [34]. Aconitase and
fumarase activities were determined according to Gardner
et al. [34], but were measured after extraction with a
medium supplemented with citrate sodium (1 M) in order
to stabilize the aconitase activity ex vivo. Values of
aconitase and fumarase activities were determined on the
same extract for each biological sample.
Respiratory chain complexes and citrate synthase
activities
Activities of the NADH-ubiquinone oxido-reductase
(complex I), succinate-ubiquinone oxido-reductase (com-
plex II), ubiquinol cytochrome c reductase (complex III),
cytochrome c oxidase (complex IV), NADH cytochrome c
reductase (activity of complex I + III) and succinate cyto-
chrome c reductase (activity of complex II + III) were
determined as previously described [35]. Heart samples
(100 mg) were homogenized at 4°C with 0.9 ml of a potas-
sium phosphate buffer 100 mM, pH 7.4. The homogenates
were centrifuged (1,500 × g, 5 min, 4°C), and the resulting
supernatants were stored at −80°C until the determination
of the various enzymatic activities. Activity of the citrate
synthase was determined according to Faloona and
Srere [36]. The activities of the respiratory chain com-
plexes and citrate synthase were expressed in units per
mg of proteins.
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The expressions of total eNOS, phosphorylated eNOS at
Ser1177 and iNOS were evaluated by Western blot. Frozen
samples were homogenized in ice-cold lysis buffer
containing 20 mM Tris (pH 7.8), 137 mM NaCl, 2.7 mM
KCl, 1 mM MgCl2, 1% Triton X-100, 10% (w/v) glycerol,
10 mM NaF, 1 mM ethylenediaminetetraacetic acid,
5 mM Na pyrophosphate, 0.5 mM Na3VO4, 1 μg/ml
leupeptin, 0.2 mM phenylmethylsulfonyl fluoride and
1 mM benzamidine. The homogenates were centrifuged
at 5,000 g for 20 min at 4°C, and the protein concentra-
tion in the supernatant was determined in each aliquot.
Protein extracts (50 μg/lane) were loaded onto a 10%
SDS gel and separated by electrophoresis. Extracts from the
control group were loaded on both gels, and the amount of
protein was accordingly compared pairwise. Proteins were
transferred to nitrocellulose membranes. The membranes
were incubated overnight at 4°C with rabbit antibodies
against total eNOS (1:150, Thermoscientific, Illkirch,
France), iNOS (1:1,000, BD Biosciences Pharmingen, Le
Pont de Claix, France) and phosphospecific mouse anti-
bodies against eNOS Ser1177 (1:1,000, BD Biosciences
Pharmingen, Le Pont de Claix, France). After being
washed in tris buffered saline (TBS)-Tween, the mem-
branes were incubated with horseradish peroxidase-
conjugated anti-mouse IgG for eNOS Ser1177 (1:3000,
Jackson Immunoresearch, Montluçon, France) and
anti-rabbit IgG for total eNOS and iNOS (1:20000,
Jackson Immunoresearch, Montluçon, France) for 1 h
at room temperature, followed by additional washing.
Proteins were visualized by enhanced chemiluminescence
with ECL advanced Western blotting detection kit
(Amersham Biosciences, Brumath, France) and quantified
using densitometry and Image J software. PAN-Actin
(1:1000, Cell Signaling Technology, St-Quentin-en-Yvelines,
France) was used as a loading control.
RNA isolation
Total RNA from rat hearts was isolated by using Tri
reagent according to instruction recommended by the
manufacturer. Briefly, 50 mg of tissue was homogenized
in 1 ml of Tri reagent (Sigma Chemical Co, Via Coger,
Paris, France) and the aqueous phase was collected after
chloroform addition. RNA was precipitated with isopro-
panol and washed with 75% ethanol. The RNA pellet
was dried and redissolved in diethylpyrocarbonate water.
The concentration and purity of RNA were determined
by measurement of absorbance at 260:280 nm. RNA
samples (2.5 μg of total RNA) were analyzed by 1%
agarose electrophoresis for control of RNA degradation.
Quantitative real-time PCR
1 μg of total RNA of each sample was primed with oligo
(dT) and reverse transcribed with SuperscriptIII reversetranscriptase (RT) (Life Technologies SAS, Saint Aubin,
France) to produce cDNA. PCR amplification of the
cDNA from the reverse transcription reaction was car-
ried out using specific primer pairs for Nos2 (nitric oxide
synthase 2, inducible; GenBank accession number:
NM_012611) and the house-keeping gene Arbp (acidic
ribosomal phosphoprotein; GenBank accession number:
NM_022402.2). Sequences of the primers for analysis of
mRNA were for Nos2 (forward): CAG GTT GAG GAT
TAC TTC TTC CA; Nos2 (reverse): TGT CAG AGT
CTT GTG CCT TTG with PCR product length of
132 bp and for Arbp (forward): CCT GCA CAC TCG
CTT CCT A; Arbp (reverse): TGA TGG AGT GAG
GCA CTG AG with PCR product length of 95 bp
(Eurogentec France SASU, Angers, France). These
primers were intron-spanning in order to avoid genomic
DNA contamination. Quantitative real-time PCR (qRT-
PCR) was then performed with a LightCycler FastStart
DNA Master SYBR Green I kit (Roche, Diagnostics,
Meylan, France) on a LightCycler 1.5 Instrument (Roche,
Diagnostics, Meylan, France) in capillaries of 20 μl
volume/capillary by adding 4 μl of Master Mix solution,
0.5 μM of Nos2 or 0.4 μM Arbp primers, 5 μl of the
sample and completing up to 20 μl with RNAse free
water. The assays were performed in duplicates. The
capillaries were then appropriately sealed, centrifuged
for few seconds at high speed and then placed into the
LightCycler. The thermal cycle conditions were 95°C for
10 min (pre-incubation) followed by 45 cycles of amplifi-
cation that were run at 95°C for 10 s, at 55°C for 10 s
and at 72°C for 10 s for Nos2 and at 95°C for 10 s, at
55°C for 5 s and at 72°C for 6 s for Arbp. Cycle threshold
values (Ct) were analyzed and the level of expression of
Nos2 gene was standardized against that of Arbp gene
detected in the same sample by using the 2-ΔΔCt
method [37].
Fatty acid composition of cardiac phospholipids
The phospholipid fatty acid composition was determined
in cardiac homogenates as previously described [38]. The
lipids were extracted according to Folch et al. [39]. The
phospholipids were separated from non-phosphorus lipids
using a Sep-pack cartridge [40]. After transmethylation,
the fatty acid methyl esters were separated and analyzed
by gas chromatography.
Other biochemical determinations
Blood glucose concentrations were determined with a
glucose analyzer (ACCU-CHECK Active, Softclix). Plasma
insulin concentrations were determined using a radio-
immunoassay kit (ICN Pharmaceuticals, Orangeburg, SC).
Plasma triglyceride and cholesterol levels were measured
using commercially available kits from Biomérieux
(Craponne, France) and Roche (Boulogne-Billancourt,
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the kit Bayer Healthcare’s analyser A1cNowW determined
in blood samples (5 μl) drawn from the rat fingers.
Proteins were measured using the bicinchoninic acid
method with a commercially available kit (Thermo Scien-
tific, Rockford, IL).
Statistical analysis
Results are presented as mean ± S.E.M. Animal weight,
heart dry weight, glycemia, activity of respiratory chain
complexes, aconitase-to-fumarase and lactate-to-pyruvate
ratios and data describing the oxidative stress and the
cardiac mechanical and vascular function (developed pres-
sure, heart rate, rate pressure product, coronary pressure,
and coronary flow) were contrasted across the two groups
by one-way analysis of variance (ANOVA). Measures
related to the action of the vasodilatation agents were
treated with repeated-measures ANOVA to test the effect
of the diabetes of ZDF rats (external factor), that of
















































Figure 1 Evolution of the body weight and food intake of the animal
7th and 11th week of life. ZL: Zucker lean rats; ZDF: Zucker Diabetic Fatty r
groups respectively. *: significantly different.their interaction. When required, group means were
contrasted with a Fisher’s LSD test. A probability (p) less
than 0.05 was considered significant. Statistical analysis
was performed using the NCSS 2004 software.
Results
General data
As shown in Figure 1, the food intake was always higher
in the ZDF compared to the ZL group (+85% at the 9th
wk of age), which provoked their increased body weight
(+21% at the day of the sacrifice). Consequently, based on
the analysis of the diet ingredients, the ZDF group con-
sumed greater amounts of fat than the lean group. The ab-
dominal fat mass was partly responsible for the increased
body weight since the mesenteric, retroperitoneal and
visceral adipose tissues were significantly heavier as shown
in Table 1. However, the heart weight of the ZDF rats did
not differ of that of the ZL animals (Table 1).
Figure 2 shows that the blood glucose concentration










s. (A) Body weight and (B) Food intake of the animals between the
ats. The number of experiments was 11 and 10 for the ZL and ZDF
Table 1 Adipose tissue and heart weights
ZL ZDF
Mesenteric AT 1.77 ± 0.09 4.94 ± 0.22*
Retroperitoneal AT 1.04 ± 0.07 4.56 ± 0.13*
Visceral AT 2.81 ± 0.02 9.50 ± 0.32*
Abdominal AT 3.85 ± 0.22 14.06 ± 0.43*
Abdominal AT/BW 0.013 ± 0.001 0.039 ± 0.001*
Heart 203 ± 12 200 ± 6
Heart weight/BW (mg/g) 0.68 ± 0.03 0.55 ± 0.02*
The number of experiments was 11 and 10 for the ZL and ZDF groups
respectively. The weight of mesenteric, retroperitoneal, visceral and abdominal
adipose tissues is expressed in g of wet weight. The abdominal adipose tissue
weight normalized to the body weight is expressed in g of wet weight per g
of body weight. The heart weight is expressed in mg of dry weight. The heart-
to-body weight ratio is expressed in mg of dry weight per g of body weight.
ZL: Zucker lean rats; ZDF: Zucker diabetic fatty rats; AT: adipose tissue; BW:
body weight; *: significantly different.
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(+276% compared to the ZL rats). The hyperglycemia
triggered an increase in HbA1c already significant at the
9th wk (+56%) and a huge augmentation of the
insulinemia (+244% at the moment of the sacrifice). The





































































Figure 2 Evaluation of circulating biochemical parameters. (A) Evolutio
hemoglobin (HbA1c) between 7th and 11th wk of life. (C) Plasma levels of
Zucker lean rats; ZDF: Zucker Diabetic Fatty rats. The number of experimen
significantly different.also significantly higher for the ZDF rats at the moment
of the sacrifice.
Oxidative stress
The mitochondrial-derived oxidative stress was estimated
in cardiac homogenates by the aconitase-to-fumarase
ratio. As shown in Figure 3A, the ratio was significantly
reduced in the ZDF group (−41%), indicating an increase
in the cardiac mitochondrial oxidative stress. The lactate-
to-pyruvate ratio in the coronary effluents (Figure 3B),
reflecting the cytosolic redox potential, was also decreased
in the ZDF group (−34%). This decrease in the cytosolic
redox potential may indicate a diminished capacity of the
system to buffer ROS and thus an increased presence of
oxidizing species as its primary outcome [30-32]. In the
heart, the global antioxidant power or the protein thiol
groups were not modified by the diabetic state of the ZDF
rats (Figure 4A). However, there was a significant increase
of 105% in the lipid peroxidation as shown by the TBARS
concentration normalized to the PUFAs content of the
cardiac membrane phospholipids (Figure 4B).
In the plasma, even though the antioxidant enzyme































n of blood glucose concentration and (B) proportion of glycated
insulin, (D) triglycerides and (E) cholesterol at 11th wk of age. ZL:






















































































































Figure 3 Oxidative stress measurements. (A) Mitochondrial oxidative stress estimated by aconitase-to-fumarase ratio. (B) Cytosolic oxidative
stress estimated by lactate-to-pyruvate ratio. (C) Enzymatic activity of glutathione peroxidase (GPx) in the plasma. (D) Antioxidant power of the
plasma estimated by the ferric reducing antioxidant power (FRAP) assay. (E) Systemic oxidative stress estimated by the disappearance of the
plasma thiol (SH) groups. ZL: Zucker lean rats; ZDF: Zucker Diabetic Fatty rats. The number of experiments was 11 and 10 for the ZL and ZDF
groups respectively. *: significantly different.
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estimated by the FRAP assay was significantly decreased
(−15,6%, Figure 3D). This was accompanied by a
decrease in the plasma thiol groups (Figure 3E), which
however did not reach significance.
Mitochondrial enzymatic activities
Citrate synthase was significantly increased (+4.5%) in
the ZDF group as shown by the values for the ZL versus
the ZDF rats in Table 2. When normalized to the
amount of myocardial proteins, the activity of the cyto-
chrome oxidase was increased in the ZDF group (+20%).
No modifications concerning the activities of the other
respiratory chain complexes were observed.
Fatty acid composition of cardiac phospholipids
The fatty acid composition of cardiac membrane phos-
pholipids was modulated by the development of diabetes
(Table 3). The SFAs were significantly increased in the
ZDF group (+24%), especially the 18:0 (+33%). This
increase partly occurred at the detriment of the MUFAs.
Indeed, all the MUFAs were reduced (−36, -27 and −42%
for the 16:1n-7, 18:1n-9 and 18:1n-7, respectively). The
n-6 PUFAs were also reduced, not only in their totality
(−18%) but also regarding the 18:2n-6 (−52%). However,the 20:3 n-6 and 20:4 n-6 were significantly increased
(+152 and +47%, respectively). The important reduction
of the n-6 PUFAs was accompanied by an increase in n-3
PUFAs (+98%). This was particularly true for the 22:5 n-3
and 22:6 n-3 levels (+130 and + 97%, respectively). Finally,
the n-6 to n-3 PUFA ratio of cardiac phospholipids was
reduced by the occurrence of diabetes (−60%).
Cardiac function study
The results of the ex vivo cardiac function are shown in
Table 4. The measured parameters were recorded when
the heart was perfused at constant flow before the infu-
sion of U46619. In the ZDF group, the RPP was reduced
(−35%) compared to the ZL group. This was due to a
reduction of the heart rate (−42%), since the left ventricle
developed pressure was slightly increased (+18.2%). The
changes in the RPP were consequently related to the
observed decrease in coronary flow (−25%), but the coron-
ary pressure was unaffected. The infusion of U46619
raised the coronary pressure from 80 mmHg to a value
close to 125 mmHg in both groups.
Coronary reactivity
Figure 5A depicts an EDD, which was similar in the two
groups, reaching 15% of dilatation as soon as 40 pmoles
Table 2 Respiratory chain complex and citrate synthase
activities
ZL ZDF
CI 1.06 ± 0.12 1.05 ± 0.08
CII 0.67 ± 0.04 0.68 ± 0.03
CIII 0.22 ± 0.03 0.23 ± 0.02
CIV 0.070 ± 0.006 0.084 ± 0.003*
CI + III 0.040 ± 0.003 0.040 ± 0.003
CII + III 0.022 ± 0.002 0.024 ± 0.002
CS 4.55 ± 0.01 4.75 ± 0.05*
The number of experiments was 11 and 10 for the ZL and ZDF groups
respectively. ZL: Zucker lean rats; ZDF: Zucker Diabetic fatty rats; CI: NADH:
ubiquinone oxidoreductase; CII: succinate-ubiquinone oxido-reductase; CIII:
ubiquinol-cytochrome-c reductase; CIV: cytochrome c oxidase; CI + III: NADH
cytochrome c reductase; CII + III: succinate cytochrome c reductase; CS: citrate
synthase. The results are expressed in mU/mg of proteins. *:
significantly different.
Figure 4 Oxidative stress in cardiac tissue. (A) Cardiac oxidative stress estimated by the disappearance of the protein thiol (SH) groups and the
antioxidant power in cardiac homogenates by the ferric reducing antioxidant power (FRAP) assay. (B) Cardiac lipid peroxidation estimated by the
thiobarbituric reducing substances (TBARS) assay normalized to the polyunsaturated fatty acid content of cardiac membrane phospholipids. ZL: Zucker
lean rats; ZDF: Zucker Diabetic Fatty rats. The number of experiments was 11 and 10 for the ZL and ZDF groups respectively. *: significantly different.
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in the ZDF group (Figure 5B) as soon as the SNP dose of
600 pmoles was injected (+14, +16 and +18% at the doses
of 600, 800 and 1000 pmoles of SNP, respectively). Finally,
the ECVA was not modified by the occurrence of diabetes
(Figure 5C).
eNOS expression and phosphorylation
The eNOS expression and its phosphorylation at Ser1177
were evaluated in aortic and cardiac homogenates of both
groups. No difference was observed between groups in the
expression and phosphorylation of the enzyme neither in
the aorta (Figures 6A and B) nor in the heart (Figures 6C
and D).
Nos2 mRNA and protein expression
The Nos2 mRNA and protein expression were evaluated
in cardiac homogenates of both groups. No difference
Table 3 Fatty acid composition of cardiac phospholipids
Fatty acids (%) ZL ZDF
14:0 0.07 ± 0.01 0.05 ± 0.01*
DMA16:0 2.67 ± 0.15 4.39 ± 0.60*
16:0 12.63 ± 0.17 13.25 ± 0.58
DMA18:0 1.20 ± 0.06 1.29 ± 0.25
18:0 19.37 ± 0.50 25.70 ± 1.12*
SFA 35.94 ± 0.80 44.68 ± 1.07*
16:1n-7 0.56 ± 0.02 0.37 ± 0.02*
18:1n-9 3.49 ± 0.16 2.53 ± 0.08*
18:1n-7 5.77 ± 0.22 3.32 ± 0.10*
MUFA 9.81 ± 0.36 6.21 ± 0.16*
18:2n-6 32.94 ± 1.83 15.65 ± 2.57*
20:2n-6 0.17 ± 0.02 0.17 ± 0.01
20:3n-6 0.40 ± 0.05 1.01 ± 0.11*
20:4n-6 16.01 ± 0.83 23.62 ± 1.64*
22:4n-6 0.42 ± 0.04 0.38 ± 0.03
22:5n-6 0.31 ± 0.01 0.39 ± 0.04
n-6 PUFA 50.25 ± 0.94 41.23 ± 1.27*
20:5n-3 0.10 ± 0.01 0.08 ± 0.06
22:5n-3 0.55 ± 0.06 1.26 ± 0.11*
22:6n-3 3.31 ± 0.41 6.51 ± 0.55*
n-3 PUFA 3.95 ± 0.43 7.86 ± 0.64*
PUFA 54.20 ± 0.63 49.09 ± 1.17*
n-6/n-3 13.51 ± 1.70 5.40 ± 0.47*
Total 16:0 15.30 ± 0.28 17.63 ± 0.30*
Total 18:0 20.57 ± 0.54 26.00 ± 0.94*
Total 18:1 9.26 ± 0.35 5.87 ± 0.16*
EPA/AA 0.006 ± 0.001 0.004 ± 0.001*
EPA + DHA 3.4 ± 0.4 6.6 ± 0.6*
Values are expressed as relative amounts of the total fatty acid content. The
analysis was performed on 5 samples randomly selected in each group. ZL:
Zucker lean rats; ZDF: Zucker diabetic fatty rats; DMA: dimethylacetal; SFA:
saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA:
polyunsaturated fatty acids; EPA: eicosapentanoic acid; AA: arachidonic acid;
DHA: docosahexaenoic acid; *: significantly different.
Table 4 Ex vivo cardiac function
ZL ZDF
HR (beats/min) 294 ± 10 171 ± 23*
LVDP (mmHg) 99 ± 6 115 ± 6*
RPP (mHg/min) 29 ± 2 19 ± 2*
CF (ml/min) 14.1 ± 1.0 10.6 ± 0.8*
CP before U46619 (mmHg) 78 ± 8 78 ± 3
CP after U46619 (mmHg) 121 ± 9 130 ± 8
The number of experiments was 11 and 10 for the ZL and ZDF groups
respectively. ZL: Zucker lean rats; ZDF: Zucker Diabetic fatty rats; HR: Heart
Rate, LVDP: Left Ventricle Developed Pressure, RPP: Rate x Pressure Product,
CF: Coronary Flow, CP: Coronary Pressure. * significantly different.
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protein level (Figure 7B).
Surprisingly, after using anti-iNOS antibody, a band of
95-kDa protein instead of 130 kDa was revealed. This
could represent a breakdown product of iNOS but the
harvest storage and analysis conditions were designed to
minimize proteolysis. These experiments were repeated
several times but the 130-kDa band never appeared
which is consistent with findings by other authors that
tried to detect iNOS in cardiac or skeletal muscle tissue
[41,42]. It could thus be possible that this 95-kDa band
could represent a novel isoform or an alternatively
spliced form of iNOS as previously proposed [41].
Furthermore, the evaluation of its mRNA expression
indicated the presence of Nos2 mRNA in the samples
and gave results that were in accordance with the Western
blot findings.
Discussion
Even though several studies have examined the effects of
diabetes on the vascular function, most of them used tech-
niques of isolated vessels and most of them examined the
late stages of diabetes [22,43]. This is the first study that
focuses on the effects of T2D on the intact coronary mi-
crovasculature at the early phase of the disease. This study
addressed cardiac mechanical function in an isolated heart
model that provided also the opportunity to study the
vascular functionality in the intact coronary circulation.
This allowed the analysis of the coupling of cardiac and
coronary function, which is not feasible in isolated vessels.
The ZDF rat has been well characterized as experi-
mental model of T2D. The ZL rats in our study ate a
normal amount of diet (approximately 20 g/day) and
exhibited a low blood glucose concentration (1 g/l) and
proportion of HbA1c (approximately 4%) between the
7th and 11th wk of life. Their insulinemia was also low
(1 μg/l) at the moment of sacrifice. In contrast, the ZDF
animals consumed greater amounts of food (more than
30 g/day) that resulted to a higher body weight during
the whole course of the experiment. Their blood analysis
revealed a glycemia reaching 5 g/l at the 9th wk of age
and a proportion of HbA1c close to 9% representing an
already established diabetic state. The insulinemia at the
11th week was almost 4 times higher than that of the ZL
control animals, indicating functional β cells in the
Langerhans islets despite the high blood glucose concen-
tration. Furthermore, their plasma triglycerides and
cholesterol levels were approximately 2 times higher
than those of the lean animals. All these characteristics
associated with the fact that the visceral fat mass was ab-
normally high, clearly demonstrate that the ZDF animals
displayed a severe insulin resistance responsible for the
development of type-2 diabetes, which corresponds to a
stage of early human type 2 diabetes.
Figure 5 Coronary microvascular reactivity ex vivo. (A) Endothelial-dependent dilatation (EDD). (B) Endothelial-independent dilatation (EID).
(C) Endothelial cell vasodilatation activity (ECVA). ZL: Zucker lean rats; ZDF: Zucker Diabetic Fatty rats; Ach: acetylcholine; SNP: sodium
nitroprusside. The number of experiments was 11 and 10 for the ZL and ZDF groups respectively. *: significantly different.
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enhanced cytosolic and mitochondrial oxidative stress in
the hearts of the ZDF rats as observed by the lactate-to
-pyruvate and aconitase-to-fumarase ratios respectively.
It seems though that the respiratory chain complexes
(RCC) were not implicated in the development of this
mitochondrial oxidative stress, especially since the com-
plex IV (CIV) activity was increased in the ZDF animals.
It has been previously proposed that an up-regulation of
CIV activity without any other changes in the other RCC
or citrate synthase activities may serve to reduce any
production of oxidative stress by the electron transport
chain and improve the electron flux [44], but no mea-
surements of mitochondrial respiration were performed
in this study in order to directly evaluate the mitochon-
drial function that could be related to the observed
depressed cardiac mechanical work. However, it is prob-
able that a lack of mitochondrial antioxidant defenses
could result to the increased mitochondrial oxidative
stress observed n this study. The increased oxidative
stress was also demonstrated in cardiac level by the
TBARS results as already shown in the literature [22].
This could have been the result of the observed increasein the n-3 PUFA content of the cardiac membrane phos-
pholipids of the ZDF hearts, since n-3 PUFAs are highly
susceptible to peroxidation. A hyperglycemia-induced
ROS production could have resulted to the observed in-
creased lipid peroxidation due to the elevated n-3 PUFA
content of membrane phospholipids.
The evaluation of the global plasma antioxidant capacity
of ZDF rats was significantly decreased despite the
increase of the GPx enzyme activity even though specific
activities of other antioxidant enzymes such as thioredoxin
reductase or other peroxidases were not determined. This
indicates an increased presence of ROS in their plasma as
evidenced also by the disappearance of the plasma thiol
groups, even though it did not reach absolute significance
(p = 0.079, ANOVA). The observed hyperglycemia and
hyperinsulinemia could have also induced the NADPH
oxidase activity and the consequent production of H2O2
[45] that could explain the increased activity of GPx. The
elevated activity of GPx may thus reflect a protective
response against increased oxidative stress, since oxidative
stress-induced antioxidant adaptive response could be
particularly important in high ROS environments. Thus,




Figure 6 Protein expressions of total eNOS and phosphorylated eNOS at Ser1177 in aortas and hearts. (A) Representative immunoblots
of total eNOS, eNOS phosphorylated at Ser1177 and actin in aorta. Control is the common sample used for all Western blots. (B) Quantified total
eNOS and phosphorylated eNOS in the aortas and ratio between the phosphorylated and total eNOS in aorta. (C) Representative immunoblots of
total eNOS, eNOS phosphorylated at Ser1177 and actin in heart. Control is the common sample used for all Western blots. (D) Quantified total
eNOS and phosphorylated eNOS in the hearts and ratio between the phosphorylated and total eNOS. ZL: Zucker lean rats; ZDF: Zucker Diabetic
Fatty rats. The number of experiments was 11 and 10 for the ZL and ZDF groups respectively. *: significantly different.
Figure 7 Expression levels of iNOS protein and Nos2 gene in hearts. (A) Representative immunoblots of iNOS and actin in hearts.
(B) Quantified iNOS in heart normalized to actin levels. (C) mRNA expression levels of Nos2 expressed in cycle threshold values (Ct) normalized to
the house-keeping gene Arbp. ZL: Zucker lean rats; ZDF: Zucker Diabetic Fatty rats. The number of experiments was 11 and 10 for the ZL and
ZDF groups respectively.
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despite the effort of the organism (CIV and GPx activities)
to eliminate it.
The development of T2D also induced changes in the
fatty acid profile of cardiac membrane phospholipids
that may influence lipid-protein interactions, inflamma-
tion and related metabolic processes. In particular, an
increase in the SFAs in cardiac membranes was observed
to the detriment of MUFAs. This increased degree of
saturation could negatively affect the membrane fluidity
and increase its rigidity. However, an increase in the
PUFAs content, in particular the C20:4 n-6 (arachidonic
acid, AA), C22:5 n-3 (docosapentaenoic acid, DPA) and
C22:6 n-3 (docosahexaenoic acid, DHA) contents, was
observed probably as an effort to maintain a proper
membrane fluidity degree. Moreover, these increases
seem to result from stimulation of the desaturation and
elongation enzymes in the organism of the ZDF rats ra-
ther from an increase in the concentration of the initial
phospholipids of the PUFAs metabolisms (e.g. C18:2 n-6
and C20:5 n-3 for n-6 and n-3 respectively). It has been
observed that tissues such as heart, kidney and liver
from diabetic rats are characterized by a decrease in
arachidonylated phospholipids and an increase in phos-
pholipids containing linoleic acid (LA, C18:2 n-6). How-
ever, these modifications are mostly related to the later
stages of diabetes. The n-3 and n-6 PUFAs of membrane
phospholipids are also responsible for the production of
anti- and pro-inflammatory molecules respectively. The
low ratio EPA (eicosapentanoic acid)/AA found in our
ZDF rats predisposes to a balance of eicosanoids
favouring platelet aggregation and inflammatory medi-
ator signaling [46]. The development of a compensatory
mechanism might thus be in question as the levels of
n-3 PUFAs were increased in the ZDF group. Low
levels of EPA + DHA have been related to increased risk
for sudden cardiac death [46] and hearts with high DHA
content present very low in vivo and in vitro vulnerability
to arrhythmia [47]. The ZDF hearts have high levels of
EPA +DHA in order to reduce pro-inflammatory eicosa-
noids and cytokines. These modifications in the PUFAs
levels of the cardiac membrane phospholipids probably
help the heart to resist to any sudden cardiac damage at
this early phase of diabetes [47].
In our study, we reported a strong decrease in the
ex vivo cardiac function as already shown in pre-diabetic
[48] and diabetic [49,50] states, even though Daniels
et al. [51] did not found an impaired in vivo cardiac
function in db/db mice until 18 weeks of age. This could
reflect the fact that in our study we have used an ex vivo
heart perfusion model where the perfusion buffer is
similar for both control and diabetic groups while the
diabetic hearts in vivo are submitted to different plasma
substrate and hormone concentrations than the controlones. In our ex vivo model, the RPP was significantly
reduced, mainly because of the decreased heart rate. The
T2D-induced reduction of the heart rate has already
been commonly shown in the diabetic state [52] and it
has been explained by an abnormal functioning of the
cells involved in the generation and transfer of the elec-
tric influx triggering the cardiac contraction [53]. We
also observed a noticeable diabetes-induced decrease in
the coronary flow. This decrease could also be respon-
sible for the reduction of the heart rate and cardiac
mechanical work through insufficient oxygen supply.
This could not be explained by an increase in the vascu-
lar tone triggering vasoconstriction and limitation of the
oxygen and substrate supply since no abnormalities of
the vascular function were observed according to the
results of the vascular reactivity. Finally, the two phe-
nomena could be synergistic and lead to the decreased
RPP. In contrast, the left ventricle developed pressure
was increased, which could compensate for the de-
creased heart rate. This phenomenon could be related to
the action of sarcoplasmic reticulum Ca2+ ATPase
(SERCA) whose levels have been shown to be increased
in early diabetes and especially stimulated by the pres-
ence of insulin [54] but were not evaluated in this work.
Thus, our data confirm a decrease in the ex vivo cardiac
function, and particularly in the heart rate, at this model
of heart perfusion, which is a common characteristic of
all types of diabetes.
The underlying mechanism, which could explain the
observed decreased cardiac mechanical work, has been
already characterized. Several metabolic modifications in
our study suggest that the reduced ex vivo cardiac func-
tion was due to this mechanism. In this study, we found
an increased plasma triglyceride concentration that
could allow the excess free fatty acid uptake and
stimulation of the peroxisome proliferator-activated re-
ceptor alpha (PPARα) [50]. This would lead to increased
β-oxidation and mitochondrial oxygen consumption [55].
The resulting excessive mitochondria-related ROS pro-
duction, as evidenced by the aconitase-to-fumarase ratio
in our study, would favour the expression of protein 53
(p53). The observed increased activity of the cytochrome
c oxidase suggests an increased expression of the cyto-
chrome c oxidase 2 (SCO2). Consequently, ectopic lipid
accumulation may occur in the cardiomyocytes through
increased expression of the fatty acid translocase protein
FAT/CD36. Lipotoxicity then contributes to cardiac
cell damages and myocardial dysfunction. A severe
intramyocardial lipid accumulation, even at 8 wk of age
[56] and an increased fatty acid oxidation [49] have been
observed in ZDF rats. Thus, the altered myocardial sub-
strate utilization affecting the mitochondrial function and
stimulating the above described mechanism could be one
of the factors responsible for the development of the T2D-
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reduction of oxygen demand and subsequent decrease in
the coronary perfusion. In our study though we did not
observe any decrease in the left ventricle developed pres-
sure that could have resulted from this mechanism. In-
stead, the heart rate was the parameter mostly affected by
the diabetes in our study. However, the conditions of the
perfusion model did not allow us to evaluate correctly the
left ventricle developed pressure. A future study of heart
perfusion at stable heart rate (pacing) in order to evaluate
the cardiac contractility and relaxation by measuring the
maximal rate of the ventricular pressure rise (dP/dtmax)
and fall (dP/dtmin) respectively could enlighten our know-
ledge concerning this mechanism. Taken together, these
observations suggest that the lipid accumulation and alter-
ations of substrate utilization in ZDF rats may affect firstly
the cells responsible for the cardiac contraction that are
involved in the generation and transfer of the electric in-
flux. Furthermore, hyperglycemia and insulin resistance,
two states that characterized the ZDF rats in this study,
have been related to damages in cardiac nodal cells and to
cardiac electrophysiological properties.
The effects of the T2D on the function of the coronary
resistance arteries were also evaluated in this ex vivo
model of isolated perfused heart through measurement
of the coronary reactivity. This parameter was estimated
through changes in the global coronary tone which
mainly reflects the function of the arteriole network,
since atherosclerosis does not occur in the rat [57]. The
effects of T2D on the heart can thus be evaluated inde-
pendently of the development of coronary artery disease.
In this study, the EDD of diabetic hearts was fully
maintained while the EID was even enhanced. We also
evaluated indirectly the NO production through mea-
surements of the expression and phosphorylation of the
cardiac and aortic eNOS, since the phosphorylation of
the enzyme at this site has been shown to increase NO
production [58], and that of the iNOS levels, since it has
been shown that under diabetic conditions stress-
induced iNOS is able to produce an abnormal amount
of NO [59]. In our study though, diabetes did not modify
neither cardiac iNOS levels nor the expression and
phosphorylation of eNOS at Ser1177, even though stud-
ies concerning other phosphorylation sites or the cGMP
signaling pathway were not performed. It has been re-
cently shown that the formation of superoxide from
uncoupled bovine eNOS in endothelial cell can be stim-
ulated by this kind of phosphorylation [60]. The pres-
ence of increased oxidative stress in the diabetic hearts
of the ZDF rats could have led to the depletion of
tetrahydrobiopterin (BH4) and uncoupling of the eNOS.
This could result to increased production of ROS from
the enzyme even though there was no change in the
phosphorylation of eNOS at Ser1177. The consequentsuperoxide production could lead to H2O2 production,
which could have participated to the maintained EDD of
our study since it has been shown that this molecule can
act as endothelium-hyperpolarizing factor (EDHF) [61].
The maintained EDD was a surprising finding given the
huge amount of studies associating T2D and dysfunc-
tions of the coronary microcirculation [62-64]. Factors
contributing to these discrepancies are the severity of
the obesity and diabetic state studied as well as the ex-
perimental method used. Oltman et al. [22] have
reported a preservation of the coronary arteriolar dilata-
tion to Ach in isolated vessels of pre-diabetic young (8-
to 12-wk old) ZDF rats. However, in the present study,
the ZDF rats were not in a prediabetic state, but the
T2D was already developed as indicated by the blood
glucose concentration, which was already high from the
8th wk of age. Thus, it seems that the endothelial func-
tion of the intact coronary microvasculature is not af-
fected from the diabetes at this phase. The unaltered
eNOS and iNOS activities and the high levels of AA and
DHA despite the presence of oxidative stress found in
the diabetic hearts could have contributed to this
phenomenon. AA [65] and DHA [66] are known for
their vasorelaxant effects via the production of prosta-
cyclin (PGI2) and the reduction of calcium influx in vas-
cular smooth muscle cells. A future study of vascular
reactivity in the presence of a cyclo-oxygenase (COX) in-
hibitor such as indomethacin could enlighten this hy-
pothesis. Furthermore, the early diabetes could have
provoked an increased expression of SERCA [54]
favouring the calcium uptake in vascular smooth muscle
cells that could be involved in the increased EID ob-
served in the ZDF diabetic hearts of this study.
As shown by the calculated activity of endothelial cells
to induce dilatation and the evaluation of eNOS expres-
sion the phenomenon of the maintained Ach-mediated
vasodilatation was partly mediated by the activity of
endothelial cells. However, the SNP responses were en-
hanced in the ZDF rats representing an enhanced func-
tion of the smooth muscle cells of the coronary system
contributing to the maintained endothelium-dependent
dilatation. This enhanced function may be due to a
modified NO response, which could increase guanylate
cyclase activity as already shown in cases of obesity and
hypertension [67,68].
These vascular alterations may reflect a compensatory
adaptation of the cardiovascular system to support
increased cardiac work since cardiac output and stroke
volume are increased in obese and diabetic states
[69,70]. Taken also under consideration the decreased
ex vivo cardiac mechanical function observed in this
study, this adaptation seems to be essential to adjust
organ perfusion during physiological processes such as
exercise and pathological processes such as ischemic
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respond to the increased metabolic demands. These
results come in agreement with data of Oltman et. al
[22] that showed that there is no change in the Ach
response of small coronary arteries in ZDF rats at the
age of 8–12 weeks but there is a progressive impairment
until the age of 40 weeks.
Conclusions
Cardiovascular function was evaluated in young diabetic
ZDF rats using an ex vivo heart perfusion model. Our
data suggest that at the early phase of diabetes, increased
oxidative stress in tissue and plasma is already present
and probably responsible for the observed ex vivo
cardiac mechanical dysfunction. However, the heart tries
to resist by preserving the EDD of the coronary micro-
vasculature. A number of other adaptations seem to take
place at this phase of the disease such as the increased
GPx and CIV activities and the increase in the n-3
PUFAs content of the myocardial membrane. This
would help the heart to keep an adequate perfusion and
respond to any acute cardiac incident at this phase.
Thus, therapeutic interventions at this early phase of the
disease aiming at increasing the heart rate and maintaining
the observed adaptations could be an option for delaying
or decreasing the late-stage complications of the diabetes.
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